BIOSTAR PHARMACEUTICALS, INC.
BSPM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BSPM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 5 of 6 signals
Market Cap
$263
Cash Runway
1180.6 moLead Asset
xin ao xing oleanolic acid (Approved)
Next Catalyst
Phase3_Topline · Sep 1, 2030Financial data as of Sep 30, 2017.
Tracking 1 pipeline candidate · 4 clinical trials · 1 catalyst for BIOSTAR PHARMACEUTICALS, INC..
Run BIOSTAR PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOSTAR PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 5 of 6 signals · derived from public data
1180.6 months
D/E 0.15
Lead: Approved
1 candidate
1 upcoming, next in ~1463d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 13, 2026- % of float
- 7.7%
- Days to cover
- 3.0
- Shares short
- 170,439
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BSPM short interestGovernance
Frequently asked questions
What is BIOSTAR PHARMACEUTICALS, INC.'s lead drug candidate?
BIOSTAR PHARMACEUTICALS, INC.'s most advanced tracked candidate is xin ao xing oleanolic acid (Approved) for Chronic hepatitis B.
What is BIOSTAR PHARMACEUTICALS, INC.'s next catalyst?
BIOSTAR PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Com" — expected September 1, 2030.
Who is the CEO of BIOSTAR PHARMACEUTICALS, INC.?
Mr. Ronghua Wang Ph.D. is the chief executive officer of BIOSTAR PHARMACEUTICALS, INC. (BSPM).
Where is BIOSTAR PHARMACEUTICALS, INC. headquartered?
BIOSTAR PHARMACEUTICALS, INC. (BSPM) is headquartered in Xianyang, China.
What therapeutic areas does BIOSTAR PHARMACEUTICALS, INC. focus on?
BIOSTAR PHARMACEUTICALS, INC. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.